In line with these observations, recent clinical data indicate that novel combined therapies based on the inhibition of mutated IDH enzymes and induction of apoptosis in cancer cells–through, for instance, the addition of venetoclax [106,108]—could achieve very high CR rate in R/R AML patients. Here, IDH2 is linked to cancer.